Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Επικοινωνία Submitted by Δημήτρης Σπάχος on Δευ, 05/04/2015 - 10:36
